FDA Grants Accelerated Approval to INOVIO’s VOCERYQ Immunotherapy
The FDA approved VOCERYQ to reduce the frequency of surgery in adults with recurrent respiratory papillomatosis.
The FDA approved VOCERYQ to reduce the frequency of surgery in adults with recurrent respiratory papillomatosis.